Immunoprecise Antibodies Ltd reports results for the quarter ended in January - Earnings Summary

Mindwalk Holdings

14/03/2024 14:25

* Immunoprecise Antibodies Ltd  IPA.OQ  reported a quarterly
adjusted loss of 11 cents​​ per share for the quarter ended in
January, higher than the same quarter last year, when the
company reported EPS of -19 cents.  The mean expectation of
two analysts for the quarter was for a loss of 10 cents per
share. Wall Street expected results 
    * Revenue rose 20.3% to C$6.22 million from a year ago;
analysts
expected C$6.07 million. 
    * Immunoprecise Antibodies Ltd's reported EPS for the
quarter was
a loss of 11 cents​.
    * The company reported a quarterly loss of C$2.94 million.
    * Immunoprecise Antibodies Ltd shares had fallen by 4.7%
this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 20% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for
Immunoprecise
Antibodies Ltd is $7.00 

This summary was machine generated from LSEG data March 14 at
02:24 p.m. UTC. ​All figures in Canadian dollars unless
otherwise stated. (For questions concerning the data in this
report, contact Estimates.Support@lseg.com. For any other
questions or feedback, contact
RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 31 2024      -0.10          -0.11          Missed
 Oct. 31 2023      -0.13          -0.10          Beat
 Jul. 31 2023      -0.20          -0.14          Beat
 Apr. 30 2023      -0.17          -0.21          Missed